Multiomics network medicine approaches to precision medicine and therapeutics in cardiovascular diseases
Cardiovascular diseases (CVD) are the leading cause of death worldwide and display
complex phenotypic heterogeneity caused by many convergent processes, including …
complex phenotypic heterogeneity caused by many convergent processes, including …
Artificial intelligence in heart failure: friend or foe?
A Bourazana, A Xanthopoulos, A Briasoulis… - Life, 2024 - mdpi.com
In recent times, there have been notable changes in cardiovascular medicine, propelled by
the swift advancements in artificial intelligence (AI). The present work provides an overview …
the swift advancements in artificial intelligence (AI). The present work provides an overview …
Circ-Ntrk2 acts as a miR-296-5p sponge to activate the TGF-β1/p38 MAPK pathway and promote pulmonary hypertension and vascular remodelling
L Su, X Li, X Mao, T Xu, Y Zhang, S Li, X Zhu… - Respiratory …, 2023 - Springer
Abstract Background Circular RNAs (circRNAs), a novel class of non-coding RNAs, play an
important regulatory role in pulmonary arterial hypertension (PAH); however, the specific …
important regulatory role in pulmonary arterial hypertension (PAH); however, the specific …
Mendelian randomization study with clinical follow‐up links metabolites to risk and severity of pulmonary arterial hypertension
E Alhathli, T Julian, ZUA Girach… - Journal of the …, 2024 - Am Heart Assoc
Background Pulmonary arterial hypertension (PAH) exhibits phenotypic heterogeneity and
variable response to therapy. The metabolome has been implicated in the pathogenesis of …
variable response to therapy. The metabolome has been implicated in the pathogenesis of …
Emerging pharmacotherapies for the treatment of pulmonary arterial hypertension
R Auth, JR Klinger - Expert Opinion on Investigational Drugs, 2023 - Taylor & Francis
Introduction Pulmonary arterial hypertension (PAH) is a progressive and life-threatening
disease. Approved treatment options currently primarily target abnormal cell signaling …
disease. Approved treatment options currently primarily target abnormal cell signaling …
Integrating epigenetics and metabolomics to advance treatments for pulmonary arterial hypertension
ADCU Ranasinghe, MA Schwarz - Biochemical Pharmacology, 2022 - Elsevier
Pulmonary arterial hypertension (PAH) is a devastating vascular disease with multiple
etiologies. Emerging evidence supports a fundamental role for epigenetic machinery and …
etiologies. Emerging evidence supports a fundamental role for epigenetic machinery and …
Pursuing functional biomarkers in complex disease: Focus on pulmonary arterial hypertension
A major gap in diagnosis, classification, risk stratification, and prediction of therapeutic
response exists in pulmonary arterial hypertension (PAH), driven in part by a lack of …
response exists in pulmonary arterial hypertension (PAH), driven in part by a lack of …
Inhibition of DYRK1A attenuates vascular remodeling in pulmonary arterial hypertension via suppressing STAT3/Pim-1/NFAT pathway
C Lan, G Fang, C Qiu, X Li, F Yang… - Clinical and Experimental …, 2024 - Taylor & Francis
Pulmonary arterial hypertension (PAH) is characterized by progressive vascular remodeling
caused by the excessive proliferation and survival of pulmonary artery smooth muscle cells …
caused by the excessive proliferation and survival of pulmonary artery smooth muscle cells …
PARM1 drives smooth muscle cell proliferation in pulmonary arterial hypertension via AKT/FOXO3A axis
Z He, T Chang, Y Chen, H Wang, L Dai… - International Journal of …, 2023 - mdpi.com
Pulmonary arterial hypertension (PAH) is a group of severe, progressive, and debilitating
diseases with limited therapeutic options. This study aimed to explore novel therapeutic …
diseases with limited therapeutic options. This study aimed to explore novel therapeutic …
Multiomic investigations into lung health and disease
Diseases of the lung account for more than 5 million deaths worldwide and are a healthcare
burden. Improving clinical outcomes, including mortality and quality of life, involves a holistic …
burden. Improving clinical outcomes, including mortality and quality of life, involves a holistic …